InspireMD, Inc. (NSPR)
NASDAQ: NSPR · Real-Time Price · USD
3.190
+0.090 (2.90%)
At close: Feb 21, 2025, 4:00 PM
3.170
-0.020 (-0.63%)
After-hours: Feb 21, 2025, 4:29 PM EST
InspireMD Employees
As of December 31, 2023, InspireMD had 66 total employees, including 65 full-time and 1 part-time employees. The number of employees increased by 10 or 17.86% compared to the previous year.
Employees
66
Change (1Y)
10
Growth (1Y)
17.86%
Revenue / Employee
$103,348
Profits / Employee
-$427,818
Market Cap
83.21M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
NSPR News
- 9 days ago - InspireMD and NAMSA to Partner on CGUARDIANS II Pivotal Clinical Trial of the CGuard Prime™ 80 cm Carotid Stent System for Use in TCAR procedures - GlobeNewsWire
- 18 days ago - InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - InspireMD Announces First Patient Enrolled in the CGUARDIANS II Pivotal Study of the CGuard Prime Carotid Stent System in Transcarotid Artery Revascularization Procedures (TCAR) - GlobeNewsWire
- 3 months ago - InspireMD Announces Appointment of Accomplished Medical Technology Executive Scott R. Ward to its Board of Directors - GlobeNewsWire
- 3 months ago - InspireMD, Inc. (NSPR) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 4 months ago - InspireMD Announces Establishment of Global Headquarters in Miami, Florida to Support Anticipated U.S. Launch and Commercialization of the CGuard Prime Carotid Stent System - GlobeNewsWire
- 4 months ago - InspireMD Announces Approval of Investigational Device Exemption (IDE) Application for CGUARDIANS II Pivotal Study of the CGuard Prime 80cm Carotid Stent System - GlobeNewsWire
- 5 months ago - InspireMD Announces Submission of Premarket Approval Application to FDA Seeking U.S. Regulatory Approval of the CGuard™ Prime Carotid Stent System - GlobeNewsWire